NOT FOR PUBLICATION                           FILED
                    UNITED STATES COURT OF APPEALS                        DEC 3 2019
                                                                      MOLLY C. DWYER, CLERK
                                                                       U.S. COURT OF APPEALS
                           FOR THE NINTH CIRCUIT

PAINTERS AND ALLIED TRADES                      No.    18-55588
DISTRICT COUNCIL 82 HEALTH CARE
FUND, third-party healthcare payor fund; et     D.C. No.
al.,                                            2:17-cv-07223-SVW-AS

                Plaintiffs-Appellants,
                                                MEMORANDUM*
 v.

TAKEDA PHARMACEUTICALS
COMPANY LIMITED, a Japanese
Corporation; et al.,

                Defendants-Appellees.

                   Appeal from the United States District Court
                       for the Central District of California
                   Stephen V. Wilson, District Judge, Presiding

                        Argued and Submitted June 6, 2019
                               Seattle, Washington

Before: BEA, NGUYEN, and WATFORD **, Circuit Judges.

      Plaintiffs, individual patients and third-party payor Painters and Allied


      *
        This disposition is not appropriate for publication and is not precedent
except as provided by Ninth Circuit Rule 36-3.
      **
          Judge Watford was drawn to replace Judge Rawlinson. Judge Watford
has read the briefs, reviewed the record, and watched the recording of oral
argument held on June 6, 2019.
Trades District Council 82 Health Care Fund, appeal the district court’s orders

dismissing their civil claims under the Racketeer Influenced and Corrupt

Organizations Act (“RICO”) for failure to allege sufficiently proximate cause and

their state-law consumer protection claims for related reasons.

    1. We address Plaintiffs’ civil RICO proximate cause arguments in a separate

opinion filed simultaneously with this memorandum disposition, and we reverse

the district court’s holding that Plaintiffs failed sufficiently to allege Defendants’

actions and omissions were the proximate cause of their damages under RICO.1

    2. California Claims: Plaintiff Snyder alleges that Defendants—Takeda

Pharmaceuticals Co., Takeda Pharmaceuticals USA, and Eli Lilly & Co.—violated

the California Consumer Legal Remedies Act, California’s Unfair Competition

Law, and California’s False Advertising Law. See Cal. Civ. Code § 1750; Cal.


1
       We reject Defendants’ argument that Plaintiffs lack Article III standing for
failure to allege an injury in fact. We have held in the consumer fraud context that
where plaintiffs contend that they bought a product “when they otherwise would
not have done so, because [Defendants] made deceptive claims and failed to
disclose [known risks] . . . they have suffered an ‘injury in fact’” sufficient to
support Article III standing. Mazza v. Am. Honda Motor Co., 

, 595
(9th Cir. 2012). Here, Plaintiffs alleged that they purchased Actos, which they
would not have done absent Defendants’ fraudulent scheme to conceal Actos’s risk
of bladder cancer. Thus, Plaintiffs have alleged an injury in fact sufficient to
support Article III standing.
       The district court did not address Defendants’ other alternative arguments
applicable to Plaintiffs’ RICO claims or the separate arguments that Defendant Eli
Lilly raises in its answering brief regarding Plaintiffs’ RICO and state law claims.
We decline to address them in the first instance on appeal; the district court may
address those issues on remand.

                                           2
Bus. & Prof. Code §§ 17200, 17500. Each of these claims requires Snyder to plead

economic injury, causation, and reliance. Veera v. Banana Republic, LLC, 

, 776 (Ct. App. 2016). The district court held that Snyder failed

to meet the pleading standard under Federal Rule of Civil Procedure 8 for reliance.

But the district court ignored Snyder’s specific allegations in the complaint: that

(1) she was prescribed a 15 mg daily dose of Actos, (2) that prior to taking her

prescription, she “read and relied upon the Actos label,” (3) that information about

Actos’s risk of causing bladder cancer “is information that a reasonable consumer

and prescriber would consider important in making a purchasing and prescribing

decision,” and (4) that had she known that Actos increased the risk of developing

bladder cancer, “she would never have purchased and ingested the drug.” These

allegations, if true, plausibly state a claim that Snyder relied on Defendants’

misrepresentation, which caused her to purchase a drug that she otherwise would

not have bought. See Ashcroft v. Iqbal, 

, 678 (2009). Therefore, we

reverse the district court’s holding that Snyder failed to allege reliance properly.

    3. New Jersey Claim: Plaintiff Cardarelli alleges that Defendants violated the

New Jersey Consumer Fraud Act (“NJCFA”). 2 See N.J. Stat. Ann. § 56:8-1. The


2
       We reject Defendants’ argument that Plaintiffs waived their New Jersey,
Florida, Missouri, and Minnesota claims for failure to raise them in district court.
Plaintiffs raised their state law claims in their complaint and responded to
Defendants’ arguments about their state law claims in their opposition to
Defendants’ motion to dismiss.

                                           3
NJCFA has a similar proximate cause requirement to that required for civil RICO

claims. See Dist. 1199P Health & Welfare Plan v. Janssen, L.P., 

, 530–31 (D.N.J. 2011); In re Schering-Plough Corp. Intron/Temodar

Consumer Class Action, No. 2:06-CV-5774 (SRC), 

, at *31

(D.N.J. July 10, 2009). Because we conclude in the simultaneously filed opinion

that Plaintiffs have adequately alleged their damages were proximately caused for

their civil RICO claims, we likewise hold that Cardarelli has adequately alleged

proximate cause for his New Jersey claim. Therefore, we reverse the district

court’s dismissal of Cardarelli’s New Jersey claim for failure to allege proximate

cause.

    4. Florida Claim: The district court dismissed Plaintiff Buckner’s claim under

the Florida Deceptive and Unfair Trade Practices Act (“FDUTPA”) for failure to

plead damages.3 See Fla. Stat. § 501.201. But an allegation that the plaintiff

“would not have bought” a product “if he had known the product was not safe for

human consumption . . . satisfies the damages element of a FDUTPA claim.”



3
       In dismissing Buckner’s Florida claim, the district court cited a Florida case
that held that damages based on “price inflation” are “too speculative.” See
Prohias v. Pfizer, Inc., 

, 1336 (S.D. Fla. 2007). But Plaintiffs
have abandoned their excess price damages theory that Florida has rejected on
appeal. Instead, Plaintiffs pursue their quantity effect damages theory, that they
“pa[id] for more prescriptions for Actos than would have otherwise occurred
absent the RICO violations.” As explained above, Florida law supports Plaintiffs’
second theory of damages.

                                          4
Jovine v. Abbott Labs., Inc., 

, 1344 (S.D. Fla. 2011). Here,

Buckner alleges that Defendants fraudulently concealed Actos’s risk of causing

bladder cancer, and that Buckner would not have purchased Actos if she had

known about Actos’s risk of causing bladder cancer. Accordingly, we reverse the

district court’s holding that Buckner failed to plead damages in her FDUTPA

claim. 4

    5. Missouri Claim: Plaintiff Rose alleges that Defendants violated the Missouri

Merchandising Practices Act (“MMPA”). See Mo. Rev. Stat. § 407.010. Under

the MMPA, plaintiffs must plead an “ascertainable loss” that “was the result of an

unfair practice.” Thompson v. Allergan USA, Inc., 

, 1011–12

(E.D. Mo. 2014). Missouri courts measure an “ascertainable loss” under the

“benefit-of-the-bargain” rule, which “awards a prevailing party the difference

between the value of the product as represented and the actual value of the product

as received.” 

see also Plubell v. Merck & Co., 

, 715

(Mo. Ct. App. 2009). This is similar to Plaintiffs’ excess price damages theory,

which they expressly abandoned on appeal. Thus, we affirm the district court’s


4
       Defendants also argue that Buckner’s FDUTPA claim fails under Florida’s
“safe harbor” provision, which provides that the FDUTPA “does not apply to . . .
[a]n act or practice . . . specifically permitted by federal or state law.” Fla. Stat.
§ 501.212(1). But Plaintiffs allege that Defendants’ actions violated federal civil
RICO and drug labeling laws. Because we must assume Plaintiffs’ allegations are
true, Bain v. California Teachers Association, 

, 1211 (9th Cir. 2018),
Defendants are not covered by Florida’s “safe harbor” provision.

                                          5
dismissal of Plaintiff Rose’s MMPA claim.

   6. Minnesota Claim: Plaintiffs argue that Takeda violated Minnesota Statutes

§§ 325F.69(1), 325D.13, which address consumer fraud. Plaintiffs may assert

violations of these statutes only if they seek a “public benefit.” Minn. Stat.

§ 8.31(1); Ill. Farmers Ins. Co. v. Guthman, No. CV 17-270(RHK/SER), 

, at *3 (D. Minn. Sept. 7, 2017).

         Plaintiffs do not seek a public benefit, as they ask only for damages (rather

than injunctive relief), and they seek to remedy a past harm (rather than an ongoing

harm). Buetow v. A.L.S. Enters. Inc., 

, 961 (D. Minn. 2012);

Select Comfort Corp. v. Sleep Better Store, LLC, 

, 986 (D.

Minn. 2011). We affirm the district court’s dismissal of Plaintiffs’ Minnesota

claim.

         In sum, we REVERSE the district court’s dismissal of Plaintiffs’ RICO

claims for lack of proximate cause. And we REVERSE the district court’s

dismissal of Plaintiffs’ California, New Jersey, and Florida claims. But we

AFFIRM the district court’s dismissal of Plaintiffs’ Missouri and Minnesota

claims. We remand to the district court for further proceedings consistent with this

disposition. Each party shall bear its own costs on appeal.




                                            6